Our data provide direct in vivo evidence that targeting CXCR4 itself is sufficient to suppress osteoclast activation and subsequent bone resorption, thereby extending previous work focused on the general biology of osteoclasts in the tumor microenvironment. Here, CXCR4 is linked to neoplasm.